Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

• Sponsor: National Cancer Institute (NCI) (NIH)
• Overall Status: Completed
• CT.gov ID: NCT00069160
• Collaborator: (none)
• Enrollment: 48
• Location: 1
• Arms: 2
• Duration (Months): 75
• Patients Per Site Per Month: 0.6

Study Details

Study Description

Brief Summary

The purpose of this study is three-fold: 1) to examine the ability of the experimental drug tariquidar to improve chemotherapy results by blocking a protein (P-glycoprotein) on some cancer cells that acts to pump out cancer drugs; 2) examine how tariquidar interacts with the cancer drug docetaxel; and 3) evaluate the effectiveness of combination treatment with tariquidar and docetaxel in treating patients with lung, ovarian, or cervical cancer.

Patients 18 years of age and older with recurrent or metastatic (spreading) lung, cervical, or ovarian cancer who cannot benefit from any standard treatment may be eligible for this study. Candidates will be screened with a medical history and physical examination; review of pathology slides; blood and urine tests; imaging tests, including computed tomography (CT) or magnetic resonance imaging (MRI) scans; chest x-ray, electrocardiogram (EKG); and possibly echocardiogram.

Participants will undergo the following tests and procedures:

Blood draw. Blood is drawn before treatment begins to establish baseline levels for future blood tests. Blood counts are done twice weekly after chemotherapy begins.

Central venous catheter placement. A plastic tube is put into a major vein in the chest. It is used to give the study drugs or other medications, including antibiotics and blood transfusions, if needed, and to withdraw blood samples. The line is usually placed under local anesthesia in the radiology department or the operating room. It can stay in the body for months or be removed after each treatment is completed.

Chemotherapy. Treatment cycles are 21 days. Both drugs are given on day 1 of each cycle. First, tariquidar is given as a 30-minute infusion. One hour after the tariquidar infusion, docetaxel is infused over 1 hour. (For the first cycle only, docetaxel is given in divided doses one week apart and tariquidar is administered on either day 1 or day 8. The order of tariquidar administration is randomized to generate optimal pharmacokinetic data. Patients will be hospitalized for several days during this cycle to gather research data). The tariquidar dose remains the same throughout the study. Docetaxel may be increased or decreased from cycle to cycle, based on side effects.

Condition or Disease	Intervention/Treatment	Phase
Lung Neoplasms; Ovarian Neoplasms; Cervix Neoplasms; Renal Neoplasms	Drug: docetaxel; Drug: tariquidar; Other: 99mTc-sestamibi imaging	Phase 2

Detailed Description

Intrinsic and acquired drug resistance remain major obstacles in the treatment of cancer. Accumulating evidence indicates that in some malignancies P-glycoprotein (Pgp) can confer resistance, and that its reversal can improve therapeutic outcome. Clinical trials investigating Pgp antagonists have been hampered by the occurrence of unpredictable pharmacokinetic interactions, which have required dose reductions of the chemotherapeutic agents to avert excessive toxicity. Tariquidar (XR9576) is a new Pgp antagonist that is more potent and has prolonged activity. Phase I trials with paclitaxel, vinorelbine, and docetaxel have demonstrated that tariquidar (XR9576) has minimal pharmacokinetic interactions while surrogate studies have confirmed in vivo inhibition of Pgp-mediated drug transport.This study seeks to determine the pharmacokinetic interaction, if any between docetaxel and tariquidar and to evaluate the potential for activity in lung, ovarian, primary peritoneal, fallopian tube and cervical cancers. Renal cell cancer has been added in a 3/1/06 amendment. The secondary goal is to evaluate the impact of tariquidar on uptake of (99m)Tc-sestamibi in recurrent or metastatic tumors of patients with lung, ovarian, renal or cervical cancer.

Study Design

• Study Type: Interventional
• Actual Enrollment: 48 participants
• Allocation: Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Clinical Trial of the P-Glycoprotein Antagonist, Tariquidar (XR9576), in Combination With Docetaxel in Patients With Lung, Ovarian, Renal and Cervical Cancer: Analysis of the Interaction Between Tariquidar and Docetaxel
• Study Start Date: Sep 1, 2003
• Actual Primary Completion Date: Dec 1, 2009
• Actual Study Completion Date: Dec 1, 2009

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Pts who received docetaxel on day 1, 8, & tariquidar day 8,22 Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.	Drug: docetaxel; Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.; Other Names: Taxotere ; Drug: tariquidar; Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.; Other Names: XR9576 ; Other: 99mTc-sestamibi imaging; Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.; Other Names: Cardiolite
Experimental: Pts who received docetaxel on days 1, 8, & tariquidar day 1,22 Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8 and tariquidar intravenous (IV) over 30 minutes on days 1 and 22.	Drug: docetaxel; Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.; Other Names: Taxotere ; Drug: tariquidar; Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.; Other Names: XR9576 ; Other: 99mTc-sestamibi imaging; Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.; Other Names: Cardiolite

Outcome Measures

Primary Outcome Measures

1. Geometric Mean of Maximum Concentration of the Drug (Cmax) [24 hours]

   In the first cycle patients were to receive docetaxel on days 1 and 8 and to be randomized to receive tariquidar on either day 1 or 8. Thus pharmacokinetic data with and without tariquidar can be compared.

2. The Number of Participants With Adverse Events. [4 yrs 8-11 months]

   Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module.

3. Geometric Mean of Area Under Curve (AUC0)-24 [24 hours]

4. Clinical Response Rate [4 years, 8-11 months]

   Response is determined by RECIST criteria defined as changes in only the largest diameter (unidimensional measurement) of the tumor lesion. Lesions are either measurable or non-measurable. Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as >/- 20 mm with conventional techniques (CT, MRI, xray) or as >/- 10 mm with a spiral CT scan. Non-measurable lesions are defined as all other lesions (or sites of disease) including small lesions (longest diameter <20 mm with conventional techniques or <10 mm using spiral CT.

Secondary Outcome Measures

1. Percent Increase in Sestamibi Area Under Curve (AUC) in Liver After Tariquidar [3 - 24 hours]

   A significant change in the area under the curve(AUC) in liver tissue (normal tissue as a surrogate) is defined as P<0.001. A secondary objective of this study was to establish whether tariquidar (150 mg) modulates Pgp in liver. Sestamibi is a Pgp substrate that may be a surrogate for measuring drug efflux from tumors. A baseline Tc-sestamibi scan was obtained before the administration of tariquidar. A minimum of 48 hours later, on or about day 22 a single dose of tariquidar was administered, followed by a second Tc-sestamibi scan.

2. Percent Increase in Sestamibi Area Under Curve (AUC) in Tumor Tissue [3-24 hours]

   99mTc-sestamibi is a radionuclide imaging agent used to study cardiac function that has also been shown to be a substrate for P-glycoprotein- mediated drug efflux. Because of the high expression of Pgp in liver tissue, sestamibi uptake in liver tissue is often monitored as a marker of Pgp inhibition. A significant change in the area under the curve(AUC) in liver tissue (normal tissue as a surrogate) is defined as P<0.001.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients must fulfill all of the following criteria to be eligible for study admission:

• Age greater than or equal to 18 years.

• Histologic or cytologic confirmation of lung, cervical, or ovarian cancer, following at least one standard treatment regimen, and for which there is no known standard therapy capable of extending life expectancy. Female patients with primary papillary carcinoma of the peritoneum and fallopian tube cancers will be included in the latter group, as the disease entities are closely associated with epithelial ovarian carcinoma, can be difficult to distinguish, have a similar epithelial origin, and are treated in an identical manner.

• Histologic or cytologic confirmation of renal cell carcinoma (clear cell, type 1 and type II papillary chromophobe, collecting duct and medullary). Patients should have received either sunitinib or sorafenib, unless deemed ineligible for treatment with either agent. In addition,patient should either: (a) have received IL-2; (b) have been evaluated for therapy with Interleukin-2 (IL- 2) and deemed to be ineligible; or (c) have been evaluated for therapy with IL2 and refused treatment.

• Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2

• Life expectancy of 3 months or greater.

• Suitable candidate for receiving planned therapy as evidenced by screening laboratory assessments hematologic, renal hepatic, and metabolic functions, platelet count greater than or equal to 90,000/mL, absolute granulocyte count(AGC) greater than or equal to 1,500/mL, serum creatinine greater than or equal to 1,500/mL, serum creatine less than or equal to 1.5 mg/dl )or if greater than 1.5 a measured 24 hour creatinine clearance greater than or equal to 50 mL/min) and serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 2.5 x normal limit (NL) and bilirubin less than or equal to 1.5 x NL (in patients with clinical evidence of Gilbert's disease,less than or equal to 3 x NL).

• Patients must be greater than or equal to 4 weeks prior radiation or chemotherapy, greater than 2 weeks from hormonal therapy; greater than 4 weeks from prior experimental therapy; greater than 6 weeks from mitomycin C; and greater than 8 weeks from prior UCN01 treatment.

• No serious intercurrent medical illness.

• Measurable disease by radiographic means or physical examination. For ovarian cancer, assessable disease by cancer antigen 125 (CA125) measurement is allowed.

• Willingness to sign a written consent form, and to comply with the protocol.

Exclusion Criteria:

• The following patient populations are not eligible for this study.

• Pregnant or nursing women are not eligible; women of childbearing age must agree to use an effective method of contraception. Pregnant women are not eligible because of teratogenic effects of chemotherapy.

• The presence of a second malignancy that has not received primary treatment or would complicate the primary objective of this study.

• Patients who are poor medical risk because of active, uncontrolled infection or other nonmalignant systemic disease.

• Human immunodeficiency virus (HIV) seropositive patients. Patients infected with the HIV virus will be excluded from this trial because the effect of the combination of tariquidar and docetaxel on HIV replication and/or the immune system is unknown and potentially harmful.

• Patients receiving agents which have major interactions with the cytochrome P450 3A4 (CYP3A4)drug metabolizing system and which cannot be discontinued may not be included in the trial.

• Untreated brain metastases (or local treatment of brain metastases within the last 6 months) due to the poor prognosis of these patients and difficulty ascertaining the cause of neurologic toxicities.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	National Institutes of Health	Bethesda	Maryland	United States	20892

Sponsors and Collaborators

• National Cancer Institute (NCI)

Investigators

• Principal Investigator: Susan E Bates, M.D., NCI, NIH

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Medline Plus
• Drug Information
• U.S. FDA Resources

Publications

• Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet. 1985 Mar;11(2):117-26.
• Beck WT, Cirtain MC, Lefko JL. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts. Mol Pharmacol. 1983 Nov;24(3):485-92.
• Ling V, Thompson LH. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol. 1974 Feb;83(1):103-16.

• ClinicalTrials.gov Identifier: NCT00069160
• Other Study ID Numbers: 030284; 03-C-0284; 030284; NCT00072202
• First Posted: Sep 16, 2003
• Last Update Posted: Oct 12, 2012
• Last Verified: Sep 1, 2012

• Keywords provided by , ,: Pharmacokinetics; Pharmacodynamics; Multidrug Resistance Reversal; Molecular Target; P-Glycoprotein Inhibition; Lung Cancer; Ovarian Cancer; Cervical Cancer; Renal Cancer
• Additional relevant MeSH terms: Neoplasms; Uterine Cervical Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Kidney Neoplasms; Docetaxel; Technetium Tc 99m Sestamibi

Study Results

Participant Flow

Arm/Group Title	Pts Who Received Docetaxel on Day 1, 8, & Tariquidar Day 8,22	Pts Who Received Docetaxel on Days 1, 8, & Tariquidar Day 1,22
Arm/Group Description	Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg tariquidar dose.	Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8 and tariquidar intravenous (IV) over 30 minutes on days 1 and 22.From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg tariquidar dose.
Period Title: Overall Study
STARTED	23	25
COMPLETED	23	25
NOT COMPLETED	0	0

Baseline Characteristics

Arm/Group Title	Pts Who Received Docetaxel on Day 1, 8, & Tariquidar Day 8,22	Pts Who Received Docetaxel on Days 1, 8, & Tariquidar Day 1,22	Total
Arm/Group Description	Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg tariquidar dose.	Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8 and tariquidar intravenous (IV) over 30 minutes on days 1 and 22.From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg tariquidar dose.	Total of all reporting groups
Overall Participants	23	25	48
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%
Between 18 and 65 years	19 82.6%	20 80%	39 81.3%
>=65 years	4 17.4%	5 20%	9 18.8%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	50.76 (9.54)	55.77 (9.57)	53.37 (9.79)
Sex: Female, Male (Count of Participants)
Female	18 78.3%	20 80%	38 79.2%
Male	5 21.7%	5 20%	10 20.8%
Region of Enrollment (participants) [Number]
United States	23 100%	25 100%	48 100%

Outcome Measures

1. Primary Outcome

Title	Geometric Mean of Maximum Concentration of the Drug (Cmax)
Description	In the first cycle patients were to receive docetaxel on days 1 and 8 and to be randomized to receive tariquidar on either day 1 or 8. Thus pharmacokinetic data with and without tariquidar can be compared.
Time Frame	24 hours

Outcome Measure Data

Analysis Population Description

Docetaxel alone (C1D1 = 21 patients; C1D8 = 18 patients) Docetaxel with Tariquidar (C1D1 = 21 patients; C1D8 = 16 patients) Data were evaluable in 39 patients. Paired data from 31 participants were evaluable.

Arm/Group Title	Docetaxel Alone	With Tariquidar
Arm/Group Description	40 mg/m^2 docetaxel over 1 hour on days 1 and 8.	40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on either day 1 or 8 and then again on day 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose of tariquidar.
Measure Participants	39	37
C1D1	1315	1093
C1D8	1060	1026
Both Groups (C1D1 + C1D8)	1190	1063

2. Primary Outcome

Title	The Number of Participants With Adverse Events.
Description	Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module.
Time Frame	4 yrs 8-11 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Patients on Docetaxel on Days 1, 8 & Tariquidar on Day 8, 22	Patients on Docetaxel on Days 1, 8 & Tariquidar on Days 1, 22
Arm/Group Description	Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.	Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.
Measure Participants	23	25
Number [participants]	23 100%	25 100%

3. Primary Outcome

Title	Geometric Mean of Area Under Curve (AUC0)-24
Time Frame	24 hours

Outcome Measure Data

Analysis Population Description

Docetaxel alone (C1D1 = 21 patients; C1D8 = 18 patients) Docetaxel with Tariquidar (C1D1 = 21 patients; C1D8 = 16 patients) Pharmacokinetic data were evaluable in 39 patients. Paired data from 31 participants were evaluable.

Arm/Group Title	Docetaxel Alone	With Tariquidar
Arm/Group Description	40 mg/m^2 docetaxel over 1 hour on days 1 and 8.	40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on either day 1 or 8 and then again on day 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose of tariquidar.
Measure Participants	39	37
C1D1	1367	1409
C1D8	1308	1327
Both Groups (C1D1 + C1D8)	1339	1373

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Docetaxel Alone, With Tariquidar
	Comments
	Type of Statistical Test	Superiority or Other
	Comments
Statistical Test of Hypothesis	p-Value	>.05
	Comments
	Method	t-test, 2 sided
	Comments

4. Primary Outcome

Title	Clinical Response Rate
Description	Response is determined by RECIST criteria defined as changes in only the largest diameter (unidimensional measurement) of the tumor lesion. Lesions are either measurable or non-measurable. Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as >/- 20 mm with conventional techniques (CT, MRI, xray) or as >/- 10 mm with a spiral CT scan. Non-measurable lesions are defined as all other lesions (or sites of disease) including small lesions (longest diameter <20 mm with conventional techniques or <10 mm using spiral CT.
Time Frame	4 years, 8-11 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	All Patients Who Received Docetaxel and Tariquidar
Arm/Group Description	Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.
Measure Participants	48
Number [Percentage of participants]	8 34.8%

5. Secondary Outcome

Title	Percent Increase in Sestamibi Area Under Curve (AUC) in Liver After Tariquidar
Description	A significant change in the area under the curve(AUC) in liver tissue (normal tissue as a surrogate) is defined as P<0.001. A secondary objective of this study was to establish whether tariquidar (150 mg) modulates Pgp in liver. Sestamibi is a Pgp substrate that may be a surrogate for measuring drug efflux from tumors. A baseline Tc-sestamibi scan was obtained before the administration of tariquidar. A minimum of 48 hours later, on or about day 22 a single dose of tariquidar was administered, followed by a second Tc-sestamibi scan.
Time Frame	3 - 24 hours

Outcome Measure Data

Analysis Population Description

Percent increase in sestamibi AUC in liver after tariquidar.

Arm/Group Title	All Patients Who Received Docetaxel and Tariquidar
Arm/Group Description	Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.
Measure Participants	35
Median (Full Range) [percent increase in sestamibi AUC]	82.2

6. Secondary Outcome

Title	Percent Increase in Sestamibi Area Under Curve (AUC) in Tumor Tissue
Description	99mTc-sestamibi is a radionuclide imaging agent used to study cardiac function that has also been shown to be a substrate for P-glycoprotein- mediated drug efflux. Because of the high expression of Pgp in liver tissue, sestamibi uptake in liver tissue is often monitored as a marker of Pgp inhibition. A significant change in the area under the curve(AUC) in liver tissue (normal tissue as a surrogate) is defined as P<0.001.
Time Frame	3-24 hours

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	All Patients Who Received Docetaxel and Tariquidar
Arm/Group Description	Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.
Measure Participants	31
Median (Full Range) [Percent]	12.4

Adverse Events

Time Frame	4 years and 11 months
Arm/Group Title	Patients on Docetaxel on Days 1, 8 & Tariquidar on Day 8, 22		Patients on Docetaxel on Days 1, 8 & Tariquidar on Days 1, 22
Arm/Group Description	Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.		Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.
All Cause Mortality
	Patients on Docetaxel on Days 1, 8 & Tariquidar on Day 8, 22		Patients on Docetaxel on Days 1, 8 & Tariquidar on Days 1, 22
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	Patients on Docetaxel on Days 1, 8 & Tariquidar on Day 8, 22		Patients on Docetaxel on Days 1, 8 & Tariquidar on Days 1, 22
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	6/23 (26.1%)		8/25 (32%)
Cardiac disorders
CARDIOVASCULAR (GENERAL):: Hypotension	0/23 (0%)	0	1/25 (4%)	1
CARDIOVASCULAR (GENERAL):: Thrombosis/embolism	0/23 (0%)	0	2/25 (8%)	2
Gastrointestinal disorders
GASTROINTESTINAL:: Anorexia	0/23 (0%)	0	1/25 (4%)	1
HEMORRHAGE:: Rectal bleeding/hematochezia	0/23 (0%)	0	1/25 (4%)	1
General disorders
CONSTITUTIONAL SYMPTOMS:: Fatigue (lethargy, malaise, asthenia)	1/23 (4.3%)	1	0/25 (0%)	0
CONSTITUTIONAL SYMPTOMS::	1/23 (4.3%)	1	2/25 (8%)	2
CONSTITUTIONAL SYMPTOMS:: Rigors, chills	1/23 (4.3%)	1	0/25 (0%)	0
Infections and infestations
INFECTION/FEBRILE NEUTROPENIA:: Febrile neutropenia (fever of unknown origin without clinically or m	0/23 (0%)	0	1/25 (4%)	1
Investigations
BLOOD/BONE MARROW:: Leukocytes (total WBC)	1/23 (4.3%)	1	1/25 (4%)	1
BLOOD/BONE MARROW:: Neutrophils/granulocytes (ANC/AGC)	0/23 (0%)	0	1/25 (4%)	1
HEPATIC:: Alkaline phosphatase	0/23 (0%)	0	1/25 (4%)	1
HEPATIC:: SGOT (AST) (serum glutamic oxaloacetic transaminase)	0/23 (0%)	0	1/25 (4%)	1
HEPATIC:: SGPT (ALT) (serum glutamic pyruvic transaminase)	0/23 (0%)	0	1/25 (4%)	1
Metabolism and nutrition disorders
METABOLIC/LABORATORY:: Hyponatremia	0/23 (0%)	0	1/25 (4%)	1
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL:: Musculoskeletal-Other (Specify,musculoskeletal-lethargic)	1/23 (4.3%)	1	0/25 (0%)	0
MUSCULOSKELETAL:: Muscle weakness (not due to neuropathy)	0/23 (0%)	0	1/25 (4%)	1
Nervous system disorders
NEUROLOGY:: Dizziness/lightheadedness	1/23 (4.3%)	1	0/25 (0%)	0
NEUROLOGY:: Depressed level of consciousness	0/23 (0%)	0	1/25 (4%)	1
NEUROLOGY:: Mood alteration-anxiety, agitation	0/23 (0%)	0	1/25 (4%)	1
Renal and urinary disorders
Urinary frequency/urgency	0/23 (0%)	0	1/25 (4%)	1
Respiratory, thoracic and mediastinal disorders
PULMONARY:: Dyspnea (shortness of breath)	2/23 (8.7%)	2	3/25 (12%)	3
PULMONARY:: Pulmonary-Other (Specify,clinical deterioration)	1/23 (4.3%)	1	0/25 (0%)	0
PULMONARY:: Cough	0/23 (0%)	0	1/25 (4%)	1
Hypoxia	1/23 (4.3%)	1	1/25 (4%)	1
Pneumothorax	1/23 (4.3%)	1	1/25 (4%)	1
Skin and subcutaneous tissue disorders
DERMATOLOGY/SKIN:: Alopecia	1/23 (4.3%)	1	0/25 (0%)	0
Other (Not Including Serious) Adverse Events
	Patients on Docetaxel on Days 1, 8 & Tariquidar on Day 8, 22		Patients on Docetaxel on Days 1, 8 & Tariquidar on Days 1, 22
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	23/23 (100%)		25/25 (100%)
Blood and lymphatic system disorders
BLOOD/BONE MARROW:: Hemoglobin	18/23 (78.3%)	130	21/25 (84%)	72
BLOOD/BONE MARROW:: Leukocytes (total WBC)	18/23 (78.3%)	86	21/25 (84%)	77
BLOOD/BONE MARROW:: Lymphopenia	2/23 (8.7%)	9	4/25 (16%)	21
BLOOD/BONE MARROW:: Neutrophils/granulocytes (ANC/AGC)	19/23 (82.6%)	62	16/25 (64%)	41
BLOOD/BONE MARROW:: Platelets	7/23 (30.4%)	22	6/25 (24%)	31
BLOOD/BONE MARROW:: Transfusion: pRBCs	3/23 (13%)	5	9/25 (36%)	11
COAGULATION:: Partial thromboplastin time (PTT)	9/23 (39.1%)	17	6/25 (24%)	10
COAGULATION:: Prothrombin time (PT)	3/23 (13%)	6	4/25 (16%)	13
HEMORRHAGE:: CNS hemorrhage/bleeding	0/23 (0%)	0	1/25 (4%)	1
Cardiac disorders
CARDIOVASCULAR (ARRHYTHMIA):: Sinus tachycardia	1/23 (4.3%)	1	0/25 (0%)	0
CARDIOVASCULAR (GENERAL):: Edema	7/23 (30.4%)	18	8/25 (32%)	8
CARDIOVASCULAR (GENERAL):: Hypertension	1/23 (4.3%)	1	0/25 (0%)	0
CARDIOVASCULAR (GENERAL):: Hypotension	2/23 (8.7%)	2	1/25 (4%)	1
CARDIOVASCULAR (GENERAL):: Phlebitis (superficial)	1/23 (4.3%)	1	0/25 (0%)	0
CARDIOVASCULAR (GENERAL):: Thrombosis/embolism	2/23 (8.7%)	3	1/25 (4%)	1
CARDIOVASCULAR (ARRHYTHMIA):: Palpitations	0/23 (0%)	0	1/25 (4%)	2
Ear and labyrinth disorders
AUDITORY/HEARING:: Middle ear/hearing	1/23 (4.3%)	1	0/25 (0%)	0
PAIN:: Earache (otalgia)	0/23 (0%)	0	1/25 (4%)	1
Eye disorders
OCULAR/VISUAL:: Conjunctivitis	2/23 (8.7%)	2	0/25 (0%)	0
OCULAR/VISUAL:: Dry eye	1/23 (4.3%)	1	0/25 (0%)	0
OCULAR/VISUAL:: Tearing (watery eyes)	9/23 (39.1%)	11	6/25 (24%)	10
OCULAR/VISUAL:: Ocular/Visual-Other (Specify,___)	0/23 (0%)	0	1/25 (4%)	1
OCULAR/VISUAL:: Vision-blurred vision	0/23 (0%)	0	2/25 (8%)	2
Gastrointestinal disorders
GASTROINTESTINAL:: Anorexia	12/23 (52.2%)	21	13/25 (52%)	21
GASTROINTESTINAL:: Constipation	10/23 (43.5%)	13	4/25 (16%)	5
GASTROINTESTINAL:: Dehydration	1/23 (4.3%)	1	1/25 (4%)	1
GASTROINTESTINAL:: Diarrhea patients without colostomy	17/23 (73.9%)	33	17/25 (68%)	37
GASTROINTESTINAL:: Dyspepsia/heartburn	3/23 (13%)	5	2/25 (8%)	2
GASTROINTESTINAL:: Dysphagia, esophagitis, odynophagia (painful swallowing)	1/23 (4.3%)	1	1/25 (4%)	1
GASTROINTESTINAL:: Flatulence	1/23 (4.3%)	1	3/25 (12%)	3
GASTROINTESTINAL:: Gastrointestinal-Other (Specify,_____)	1/23 (4.3%)	1	0/25 (0%)	0
GASTROINTESTINAL:: Mouth dryness	1/23 (4.3%)	1	0/25 (0%)	0
GASTROINTESTINAL:: Nausea	13/23 (56.5%)	34	12/25 (48%)	19
GASTROINTESTINAL:: Stomatitis/pharyngitis (oral/pharyngeal mucositis)	7/23 (30.4%)	18	8/25 (32%)	13
GASTROINTESTINAL:: Taste disturbance (dysgeusia)	6/23 (26.1%)	11	10/25 (40%)	17
GASTROINTESTINAL:: Vomiting	10/23 (43.5%)	17	7/25 (28%)	8
GASTROINTESTINAL:: Mucositis due to radiation	0/23 (0%)	0	1/25 (4%)	1
GASTROINTESTINAL:: Nausea	0/23 (0%)	0	12/25 (48%)	19
HEMORRHAGE:: Rectal bleeding/hematochezia	0/23 (0%)	0	1/25 (4%)	1
General disorders
CONSTITUTIONAL SYMPTOMS:: Fatigue (lethargy, malaise, asthenia)	18/23 (78.3%)	42	21/25 (84%)	56
CONSTITUTIONAL SYMPTOMS:: Fever (in the absence of neutropenia, where neutropenia is defined as AGC<	6/23 (26.1%)	13	4/25 (16%)	5
CONSTITUTIONAL SYMPTOMS:: Rigors, chills	1/23 (4.3%)	1	0/25 (0%)	0
CONSTITUTIONAL SYMPTOMS:: Weight loss	3/23 (13%)	3	3/25 (12%)	3
PAIN:: Chest pain (non-cardiac and non-pleuritic)	4/23 (17.4%)	4	0/25 (0%)	0
Immune system disorders
ALLERGY/IMMUNOLOGY:: Allergic reaction/hypersensitivity (including drug fever)	0/23 (0%)	0	2/25 (8%)	3
ALLERGY/IMMUNOLOGY:: Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)	8/23 (34.8%)	9	3/25 (12%)	3
ALLERGY/IMMUNOLOGY:: Allergy-Other (Specify,_____)	0/23 (0%)	0	1/25 (4%)	1
Infections and infestations
INFECTION/FEBRILE NEUTROPENIA:: Catheter-related infection	1/23 (4.3%)	1	0/25 (0%)	0
INFECTION/FEBRILE NEUTROPENIA::	3/23 (13%)	3	2/25 (8%)	2
INFECTION/FEBRILE NEUTROPENIA::	1/23 (4.3%)	1	1/25 (4%)	1
INFECTION/FEBRILE NEUTROPENIA:: Infection without neutropenia	4/23 (17.4%)	7	5/25 (20%)	6
INFECTION/FEBRILE NEUTROPENIA:: Infection/Febrile Neutropenia-Other (Specify,____)	0/23 (0%)	0	1/25 (4%)	1
Investigations
HEPATIC:: Alkaline phosphatase	7/23 (30.4%)	13	2/25 (8%)	2
HEPATIC:: Bilirubin	5/23 (21.7%)	14	3/25 (12%)	7
HEPATIC:: SGOT (AST) (serum glutamic oxaloacetic transaminase)	7/23 (30.4%)	11	1/25 (4%)	1
HEPATIC:: SGPT (ALT) (serum glutamic pyruvic transaminase)	5/23 (21.7%)	6	2/25 (8%)	2
METABOLIC/LABORATORY:: CPK (creatine phosphokinase)	1/23 (4.3%)	1	1/25 (4%)	1
BLOOD/BONE MARROW:: Hemoglobin	0/23 (0%)	0	20/25 (80%)	72
METABOLIC/LABORATORY:: Hyperuricemia	1/23 (4.3%)	1	2/25 (8%)	3
Metabolism and nutrition disorders
HEPATIC:: Hypoalbuminemia	16/23 (69.6%)	36	12/25 (48%)	40
METABOLIC/LABORATORY:: Bicarbonate	1/23 (4.3%)	1	0/25 (0%)	0
METABOLIC/LABORATORY:: Hypercalcemia	1/23 (4.3%)	2	1/25 (4%)	1
METABOLIC/LABORATORY:: Hyperglycemia	10/23 (43.5%)	26	11/25 (44%)	23
METABOLIC/LABORATORY:: Hyperkalemia	2/23 (8.7%)	2	3/25 (12%)	5
METABOLIC/LABORATORY:: Hypermagnesemia	3/23 (13%)	5	3/25 (12%)	4
METABOLIC/LABORATORY:: Hypernatremia	1/23 (4.3%)	1	0/25 (0%)	0
METABOLIC/LABORATORY:: Hypocalcemia	7/23 (30.4%)	20	7/25 (28%)	21
METABOLIC/LABORATORY:: Hypoglycemia	1/23 (4.3%)	1	0/25 (0%)	0
METABOLIC/LABORATORY:: Hypomagnesemia	8/23 (34.8%)	18	4/25 (16%)	6
METABOLIC/LABORATORY:: Hyponatremia	14/23 (60.9%)	36	15/25 (60%)	26
METABOLIC/LABORATORY:: Hypophosphatemia	3/23 (13%)	9	1/25 (4%)	1
METABOLIC/LABORATORY:: Hypokalemia	5/23 (21.7%)	6	3/25 (12%)	6
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL:: Muscle weakness (not due to neuropathy)	1/23 (4.3%)	1	5/25 (20%)	7
PAIN:: Arthralgia (joint pain)	6/23 (26.1%)	9	6/25 (24%)	10
PAIN:: Bone pain	3/23 (13%)	5	4/25 (16%)	5
PAIN:: Myalgia (muscle pain)	7/23 (30.4%)	22	8/25 (32%)	12
Nervous system disorders
NEUROLOGY:: Ataxia (incoordination)	1/23 (4.3%)	1	0/25 (0%)	0
NEUROLOGY:: Confusion	1/23 (4.3%)	2	1/25 (4%)	1
NEUROLOGY:: Depressed level of consciousness	1/23 (4.3%)	1	0/25 (0%)	0
NEUROLOGY:: Dizziness/lightheadedness	5/23 (21.7%)	5	3/25 (12%)	3
NEUROLOGY:: Extrapyramidal/involuntary movement/restlessness	1/23 (4.3%)	1	0/25 (0%)	0
NEUROLOGY:: Insomnia	4/23 (17.4%)	4	3/25 (12%)	3
NEUROLOGY:: Mood alteration-depression	2/23 (8.7%)	2	2/25 (8%)	2
NEUROLOGY:: Neuropathy-sensory	6/23 (26.1%)	7	8/25 (32%)	11
NEUROLOGY:: Seizure(s)	1/23 (4.3%)	1	0/25 (0%)	0
NEUROLOGY:: Syncope (fainting	1/23 (4.3%)	1	0/25 (0%)	0
NEUROLOGY:: Vertigo	1/23 (4.3%)	1	0/25 (0%)	0
PAIN:: Neuropathic pain (e.g., jaw pain, neurologic pain, phantom limb pain, post-infectious neuralg	1/23 (4.3%)	1	0/25 (0%)	0
PAIN:: Pain-Other (Specify,___)	9/23 (39.1%)	11	2/25 (8%)	2
PAIN:: Headache	5/23 (21.7%)	5	5/25 (20%)	6
NEUROLOGY:: Mood alteration-anxiety, agitation	0/23 (0%)	0	1/25 (4%)	1
Renal and urinary disorders
RENAL/GENITOURINARY:: Creatinine	2/23 (8.7%)	2	2/25 (8%)	3
RENAL/GENITOURINARY:: Urinary frequency/urgency	2/23 (8.7%)	2	1/25 (4%)	1
HEMORRHAGE:: Hematuria (in the absence of vaginal bleeding)	0/23 (0%)	0	1/25 (4%)	2
RENAL/GENITOURINARY:: Dysuria (painful urination)	0/23 (0%)	0	2/25 (8%)	2
RENAL/GENITOURINARY:: Urinary retention	0/23 (0%)	0	2/25 (8%)	2
Reproductive system and breast disorders
PAIN:: Abdominal pain or cramping	5/23 (21.7%)	5	6/25 (24%)	8
PAIN:: Pelvic pain	0/23 (0%)	0	1/25 (4%)	1
Respiratory, thoracic and mediastinal disorders
HEMORRHAGE:: Epistaxis	2/23 (8.7%)	2	0/25 (0%)	0
PULMONARY:: Cough	9/23 (39.1%)	9	3/25 (12%)	3
PULMONARY:: Dyspnea (shortness of breath)	9/23 (39.1%)	10	7/25 (28%)	9
PULMONARY:: Pleural effusion (non-malignant)	2/23 (8.7%)	2	2/25 (8%)	5
PULMONARY:: Pulmonary-Other (Specify,___)	2/23 (8.7%)	3	0/25 (0%)	0
PULMONARY:: Voice changes/stridor/larynx (e.g., hoarseness, loss of voice, laryngitis)	1/23 (4.3%)	1	0/25 (0%)	0
PULMONARY:: Hypoxia	2/23 (8.7%)	2	1/25 (4%)	1
Skin and subcutaneous tissue disorders
DERMATOLOGY/SKIN:: Alopecia	8/23 (34.8%)	9	8/25 (32%)	10
DERMATOLOGY/SKIN:: Dermatology/Skin-Other (Specify,_____)	1/23 (4.3%)	1	0/25 (0%)	0
DERMATOLOGY/SKIN:: Dry skin	3/23 (13%)	3	1/25 (4%)	1
DERMATOLOGY/SKIN:: Erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)	1/23 (4.3%)	1	1/25 (4%)	1
DERMATOLOGY/SKIN:: Flushing	4/23 (17.4%)	7	1/25 (4%)	2
DERMATOLOGY/SKIN:: Hand-foot skin reaction	4/23 (17.4%)	5	3/25 (12%)	3
DERMATOLOGY/SKIN:: Injection site reaction	1/23 (4.3%)	1	5/25 (20%)	5
DERMATOLOGY/SKIN:: Nail changes	6/23 (26.1%)	9	8/25 (32%)	8
DERMATOLOGY/SKIN:: Radiation dermatitis	1/23 (4.3%)	1	0/25 (0%)	0
DERMATOLOGY/SKIN:: Rash/desquamation	4/23 (17.4%)	4	3/25 (12%)	4
DERMATOLOGY/SKIN:: Bruising (in absence of grade 3 or 4 thrombocytopenia)	0/23 (0%)	0	1/25 (4%)	1
DERMATOLOGY/SKIN:: Pruritus	0/23 (0%)	0	2/25 (8%)	2
DERMATOLOGY/SKIN:: Wound-non-infectious	0/23 (0%)	0	1/25 (4%)	1

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.